Arrowhead Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARWR Nasdaq 2830 arrowheadpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - Mar 10th, 2025 6:02 pm
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy - Mar 10th, 2025 11:30 am
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases - Mar 6th, 2025 1:45 pm
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Feb 28th, 2025 2:00 pm
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity - Feb 25th, 2025 12:30 pm
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now - Feb 20th, 2025 5:15 pm
ARWR: Multiple Catalysts Ahead in 2025… - Feb 12th, 2025 2:22 pm
Arrowhead Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations - Feb 12th, 2025 10:58 am
Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call - Feb 11th, 2025 3:10 pm
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... - Feb 11th, 2025 7:06 am
Arrowhead Research: Fiscal Q1 Earnings Snapshot - Feb 10th, 2025 9:08 pm
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results - Feb 10th, 2025 9:01 pm
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics - Feb 10th, 2025 1:30 pm
Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600 - Jan 22nd, 2025 10:54 pm
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results - Jan 22nd, 2025 9:00 pm
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Jan 17th, 2025 9:30 pm
Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial - Dec 24th, 2024 1:20 pm
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - Dec 23rd, 2024 12:30 pm
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Dec 19th, 2024 9:59 pm
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases - Dec 11th, 2024 12:30 pm